SJS Investment Consulting’s Design Therapeutics DSGN Stock Holding History

SJS Investment Consulting’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$58	Buy	+4	New	+$50	﹤0.01%	2713

Other funds holding DSGN

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

AlphaCentric Advisors San Juan, Puerto Rico $118M AUM

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Allied Private Wealth Boca Raton, Florida $156M AUM

Private Wealth Management Group Princeton, New Jersey $431M AUM 20.62% 1-Year Est. Return

Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

SJS Investment Consulting's DSGN Position: Q2 2026 in Review

SJS Investment Consulting opened a new position in Design Therapeutics (DSGN) in Q2 2026: 4 shares worth $58. The stake represents ﹤0.01% of the portfolio and ranks #2713 among its holdings.

18 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

SJS Investment Consulting held 4 shares of Design Therapeutics worth $58 as of Q2 2026.
Design Therapeutics was a new SJS Investment Consulting position in Q2 2026.
Design Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2713 holding.
18 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.